Compare Novavax Inc (NVAX) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Omnicom Group Inc. — how do they compare? Novavax Inc trades at $7.88 (market cap $1.31B), while Omnicom Group Inc. trades at $84.15 (market cap $23.58B). The key difference: Omnicom Group Inc. is far larger — about 18× Novavax Inc's market cap, and Omnicom Group Inc. pays a 3.72% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | OMC | |
|---|---|---|
Market Cap | $1.31B | $23.58B |
Sector | Health | Media |
52-Week High | $11.19 | $86.22 |
52-Week Low | $6.22 | $67.27 |
Enterprise Value | $889.30M | $31.66B |
Dividend Yield | — | 3.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
Omnicom Group (OMC) trades at $84.65, down 0.69% on the day, with a bullish technical outlook per moving averages but mixed oscillators. Recent Q2 2026 earnings beat expectations with $2.65 EPS, driven by 6.1% organic revenue growth and margin expansion post-Interpublic acquisition. The company maintains a 4% dividend yield and active buybacks, though high P/E of 232.3 reflects net income volatility.
Outlook is positive with analyst consensus target of $107.00 (27% upside), but risks include integration costs, debt increase, and competitive pressures. The stock offers value from synergy realization and AI-driven growth initiatives, yet investors must monitor execution on cost savings and organic growth sustainability amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
